Male Breast Cancer Clinical Trial
Official title:
A Prospective, Randomised, Multi-centre Phase II Study Evaluating the Adjuvant, Neoadjuvant or Palliative Treatmant With Tamoxifen +/- GnRH Analogue Versus Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients
A prospective, randomised multi-centre phase II study evaluating the adjuvant, neoadjuvant or palliative treatment with tamoxifen +/- GnRH analogue versus aromatase inhibitor + GnRH analogue in male breast cancer patients (MALE).
Breast cancer in men is a rare disease with approximately 0.5- 1% of all breast cancer cases.
Each year, about 400 to 450 cases are diagnosed in Germany. Men tend to present with more
advanced disease than women, probably due to the lack of awareness of male breast cancer from
both, the patient and the physicians.
Therefore, at presentation they usually have lump or nipple inversion, and more than 40% of
the patients have a stage III or IV disease. The great majority of patients have an invasive
ductal (90%), hormone receptor positive (90%), HER2 negative (90%) tumor.
The only available information on adjuvant therapies derives from few retrospective cases and
retrospective studies with a little number of cases. Therefore, treatment strategies are not
based on data from prospective, randomised clinical studies, and optimal treatment is
unknown. As a result, current clinical management is generally extrapolated from principles
established for the treatment of female breast carcinoma. As the majority of male breast
cancer patients have a hormone receptor positive tumor, they receive tamoxifen 20 mg for five
years as standard endocrine adjuvant therapy. A lot of withdrawals from the treatment were
documented in male breast cancer due to side-effects under tamoxifen therapy. Furthermore,
the clinical outcome of tamoxifen-treated male breast cancer patients may be influenced by
the activity of cytochrome P450 2D6 enzymes that catalyse the formation of anti-estrogenic
metabolites endoxifen and 4-hydroxy-tamoxifen. Therefore a significant proportion of poor to
moderate metaboliser is proposed to do not benefit from adjuvant tamoxifen therapy.
Although women benefit from adjuvant treatment with aromatase inhibitors (AI) regarding
disease-free-survival, overall survival and treatment toxicity, only case reports of men
treated with AI exist. Other data show, that under AI, there is only a suppression of
estradiol of about 40-50% with an increase of testosterone of about 50%. Among men on AIs, it
is possible that the hypothalamic-pituitary feedback loop results in an increase substrate
for aromatisation, and thus prevents complete estrogen suppression.
However, an optimal suppression (80%) of the peripheral estradiol level would be a necessary
condition for a therapeutic benefit of AI in men with breast cancer.
By adding a gonadotropin-releasing hormone analogue, the negative feedback loop would be
interrupted and complete estrogen suppression may be achieved.
In conclusion, there is a great lack on information for the treatment of male patients with
breast cancer.
Prospective multi-centre, randomised trials in men with breast cancer are necessary in order
to prove the effect of tamoxifen + GnRH analogue versus none and versus AI + GnRH analogue as
adjuvant or neoadjuvant endocrine treatment.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02480933 -
Silent Breast Cancer A Study of the Disease Prevalence Held by Imaging Guided Biopsies in Autopsy Specimens
|
N/A | |
Terminated |
NCT01705340 -
Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
|
Phase 1 | |
Terminated |
NCT01222377 -
Endoscopic Breast Surgery in Treating Patients With Breast Cancer
|
N/A | |
Completed |
NCT00244881 -
A Phase II Study of AZD2171 in Breast Cancer Stage IV (10006202)
|
Phase 2 | |
Completed |
NCT00425672 -
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00096434 -
Sorafenib in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT01217411 -
RO4929097 and Whole-Brain Radiation Therapy or Stereotactic Radiosurgery in Treating Patients With Brain Metastases From Breast Cancer
|
Phase 1 | |
Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
Active, not recruiting |
NCT00791037 -
Vaccine Therapy in Treating Patients With Stage IV Breast Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT00559507 -
Saracatinib in Treating Patients With Metastatic or Locally Advanced Breast Cancer That Cannot Be Removed By Surgery
|
Phase 2 | |
Completed |
NCT00119262 -
Bevacizumab and Combination Chemotherapy in Patients With Lymph Node Positive Breast Cancer
|
Phase 2 | |
Completed |
NCT00098605 -
Lapatinib in Treating Brain Metastases in Patients With Stage IV Breast Cancer and Brain Metastases
|
Phase 2 | |
Terminated |
NCT00095888 -
3-AP and Gemcitabine in Treating Patients With Refractory Metastatic Breast Cancer
|
Phase 2 | |
Terminated |
NCT00071942 -
Vaccine Therapy in Treating Patients With Metastatic Breast Cancer
|
Phase 1 | |
Completed |
NCT00068588 -
GTI-2040 and Capecitabine in Treating Patients With Metastatic Breast Cancer
|
Phase 2 | |
Recruiting |
NCT05501704 -
ETHAN - ET for Male BC
|
Phase 2 | |
Completed |
NCT02046421 -
Carboplatin, Gemcitabine Hydrochloride, and Mifepristone in Treating Patients With Advanced Breast Cancer or Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
Completed |
NCT01869764 -
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
|
Phase 2 | |
Completed |
NCT01720602 -
Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy
|
N/A | |
Completed |
NCT01493310 -
Nab-paclitaxel (Abraxane) With or Without Mifepristone in Patients With Advanced Breast Cancer
|
Phase 1 |